Bms-986278 clinical trial
WebIntroduction: The LPA1 receptor is implicated in IPF pathogenesis. BMS-986278 is a potent small molecule LPA1 receptor antagonist being investigated for IPF. This study evaluated the safety, tolerability, and PK of oral BMS-986278 in healthy participants (ppts). Methods: IM027-009 is a phase 1, double-blind, placebo (PBO)-controlled, randomized study in … WebOct 19, 2024 · An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants The safety and scientific validity of …
Bms-986278 clinical trial
Did you know?
WebBristol Myers Squibb is committed to sustaining its strong leadership and legacy in the development of transformational therapeutics for treating patients with malignant and benign hematological conditions. • Our focus is on Multiple Myeloma, Lymphoma and CLL, MDS, AML, MPNs (e.g., myelofibrosis) and thalassemias WebJan 13, 2024 · A Phase 1, 2-Part, Randomized, Double-Blind, Placebo-controlled, Multiple Dose Study to Test the Potential Interaction of a PDE5 Inhibitor With BMS-986278 and to …
WebThe purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and … WebBMS-986278, a second-generation LPA 1 antagonist, is currently in phase 2 development as a therapy for IPF and PF-ILD. Methods and analysis: This phase 2, randomised, … National Center for Biotechnology Information
WebPrincipal Scientist. Jun 2024 - Present2 years 11 months. New Jersey, United States. Allosteric inhibitor for fibrosis. • Performed SAR to improve the overall in-vitro and in-vivo profiling of ...
WebMar 28, 2024 · A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants March 28, 2024 updated by: Bristol-Myers Squibb A Double-blind, Placebo-controlled, Randomized, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986278 in Healthy Chinese …
WebMar 1, 2024 · Abstract. In a Phase 2 clinical trial, BMS-986020, a lysophosphatidic acid receptor-1 (LPA 6.2 μM) and inhibited BA canalicular efflux in human hepatocytes (68% … dr christopher riccioWebA Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis - IM027-040. Updated: 3 December, 2024 ... Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team dr christopher richardsWebMar 1, 2024 · BMS-986020, BMS-986234 and BMS-986278, are three lysophosphatidic acid receptor 1 (LPA1) antagonists that were or are being investigated for treatment of … dr. christopher richards-bentleyWebA Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis Latest version (submitted March 17, 2024) on ClinicalTrials.gov A … endy arfian filmWebMar 1, 2024 · BMS-986234 and BMS-986278 are both potent LPA 1 antagonists that are structurally distinct from BMS-986020 (Cheng et al., 2024) (Fig. 1).BMS-986234 was discontinued prior to clinical development due to an unfavorable nonclinical pharmacokinetic profile (Cheng et al., 2024).BMS-986278 is currently being evaluated in … endya scott san bernardino caWebFeb 3, 2024 · Clinical trial for Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers. Updated 02/03/2024. Toggle navigation. ... NCT03712540 - An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants Phase 1: … endya association courtageWebMar 1, 2024 · In a Phase 2 clinical trial, BMS-986020, a lysophosphatidic acid receptor-1 (LPA 1 ) antagonist, produced hepatobiliary toxicity (increased ALT, AST, and ALP; cholecystitis) and increases in plasma bile acids (BA). ... (BMS-986234 and BMS-986278). BMS-986020 inhibited hepatic BA efflux transporters BSEP (IC 50 1.8 μM), MRP3 (IC 50 … endy carter memphis tn